This year is nothing like last year’s SPAC attack — just seven biotech companies have opted for the SPAC route in 2021, by our count — but the fact that companies are still choosing SPACs over IPOs speaks to their continued attractiveness.

Boston Biz Journal https://www.bizjournals.com/boston/news/2021/09/13/massachusetts-boston-biotech-spac-mergers-2021.html?ana=RSS&s=article_search